Hi-Risk/Recurrent/Advanced PCa Video Chat, Jan 28, 2025

Made a donation yet? If not, now’s the time – PLEASE! It’s AnCan’s Annual Fundraiser – once a year is the only time we ask for donations.
We’ve received less than 10% from participants, viewers and those receiving the Reminder combined. Time to step up and show appreciation and gratitude if you watch these videos, find them helpful., and want them to continue. Donate now at https://ancan.org/donate/

IF YOU’RE WATCHING THIS VIDEO, PLEASE COMPLETE OUR SHORT, 7-MINUTE ANCAN 2024 SURVEY...  https://docs.google.com/forms/d/e/1FAIpQLSfw2B3rZTMWIPqTmzLYBl1CdN9qRJSpt0f72CoK6J00zllzWw/viewform  AnCan needs your feedback and we also hope to take the results to medical conferences. We will be closing out in the next couple of weeks, so no more procrastinating please!! Analysis is scheduled to start soon and we are at 454 response in total. Let’s break 500!
AnCan is grateful to the following sponsors for making this recording possible: Bayer, Foundation Medicine, Janssen, Myriad Genetics, Novartis, Telix & Blue Earth Diagnostic.
If you missed any recent recordings, you’ll find a full list either on our YouTube Playlist or visit our Blog Post https://ancan.org/our-recent-blog-posts-in-case-you-missed-them/   Sign up for our Blog by checking the New Blog box at https://ancan.org/contact-us/
AnCan respectfully notes that it does not accept sponsored promotion. Any drugs, protocols or devices recommended in our discussions are based solely on anecdotal peer experience or clinical evidence.
AnCan cannot and does not provide medical advice. We encourage you to discuss anything you hear in our sessions with your own medical team.
AnCan reminds all Participants that Adverse Events experienced from prescribed drugs or protocols should be reported to the pharmaceutical manufacturer or the FDA Adverse Event Reporting System (FAERS). To do so call 1-800-332-1066 or download interactive FDA Form 3500 https://www.fda.gov/media/76299/download
All AnCan’s groups are free and drop-in … join us in person sometime!
Join our other free and drop in groups:

Editor’s Pick: After 10 years (with a Gleason 10!) he’s ready for an ADT break. (bn)

Topics Discussed

Just three positive biopsy cores — but they’re in a bad place; five positive cores — but they’re all Gleason 3+3; he’s “an 81-year-old guy who’s been fighting cancer for 10 years” (with a Gleason 10!)  and is thinking about a drug holiday; reminders from Rick: donations are still sadly low, and there’s still time to fill out the survey; re-irradiate old metastases that no longer show up in scans?;  my docs don’t talk to each other — you’re calling that a team?; he’s never had a seizure till now — was it the Xtandi, and was it really a seizure?; should he fine-tune which statin he takes?; is prostate debulking useful for de novo men?;  does he also need spot radiation in his bones if he’s also getting ADT?; those new bone pains might be caused by metastasis, not ADT; his urologist and the MSK nomogram are way apart on prognosis.

Chat Log 

Len Sierra · 6:39 PM
https://www.mskcc.org/nomograms/prostate

AnCan  – rick · 7:02 PM
PROMISE trial  https://www.prostatecancerpromise.org/?utm_campaign=ANCAN&utm_medium=link&utm_source=Webinar

AnCan  – rick · 7:29 PM
Survey …. https://docs.google.com/forms/d/e/1FAIpQLSfw2B3rZTMWIPqTmzLYBl1CdN9qRJSpt0f72CoK6J00zllzWw/viewform

AnCan  – rick · 7:30 PM
Donations   https://ancan.org/donate/

AnCan  – rick · 8:06 PM
Study Doug is ref:  https://pmc.ncbi.nlm.nih.gov/articles/PMC3255347/#abstract1

Dr. Jeff · 8:09 PM
According to current research, rosuvastatin appears to be more effective than simvastatin in potentially preventing or managing prostate cancer based on studies showing a stronger association with reduced cancer progression and mortality, with some evidence suggesting that rosuvastatin may have a more potent anti-tumor effect compared to simvastatin; however, more research is needed to fully understand the specific differences between the two drugs in relation to prostate cancer. Several studies have indicated that rosuvastatin may be associated with a greater reduction in prostate cancer mortality compared to simvastatin.    So there are different conclusions.

AnCan  – rick · 8:15 PM
Allen Edel https://pcnrv.blogspot.com/2018/09/no-survival-benefit-to-debulking.html

Larry Schuller · 8:30 PM
Firmagon and Orgovyx are receptor antagonists.  Lupron is an agonist.  They interrupt the instructions to the testes to make testosterone but agonists have two problems.  The first is a testosterone surge (which has to be endured or suppressed) for about amonth and the second is that when you stop, it takes longer for your testosterone to recover

AnCan  – rick · 9:03 PM
gdeliguori@imppllc.com

Jim Marshall, Alexandria, VA · 9:04 PM
Ming Zhou – Ming.zhou@mountsinai.org